;PMID: 2498299 ;source_file_1892.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..41] = [t:0..41] ;1)sentence:[e:47..199] = [t:47..199] ;2)section:[e:203..231] = [t:203..231] ;3)section:[e:235..341] = [t:235..341] ;4)sentence:[e:345..524] = [t:345..524] ;5)sentence:[e:525..705] = [t:525..705] ;6)sentence:[e:706..877] = [t:706..877] ;7)sentence:[e:878..1087] = [t:878..1087] ;8)sentence:[e:1088..1363] = [t:1088..1363] ;9)sentence:[e:1364..1485] = [t:1364..1485] ;10)sentence:[e:1486..1667] = [t:1486..1667] ;11)section:[e:1671..1715] = [t:1671..1715] ;section 0 Span:0..41 ;J Biochem (Tokyo). 1989 Feb;105(2):234-8. (SEC (FRAG (NNP:[0..1] J) (NNP:[2..9] Biochem) (NN:[10..11] -LRB-) (NN:[11..16] Tokyo) (NN:[16..17] -RRB-) (.:[17..18] .) (CD:[19..23] 1989) (NNP:[24..31] Feb;105) (-LRB-:[31..32] -LRB-) (CD:[32..33] 2) (-RRB-:[33..34] -RRB-) (::[34..35] :) (CD:[35..38] 234) (::[38..39] -) (CD:[39..41] 8.))) ;sentence 1 Span:47..199 ;Purification and properties of cytochrome P-450 generally acting as a ;catalyst on benzo[a]pyrene hydroxylation from liver microsomes of untreated ;rats. ;[78..94]:cyp450:"cytochrome P-450" ;[117..125]:cyp450:"catalyst" ;[130..144]:substance:"benzo[a]pyrene" (SENT (NP-HLN (NP (NN:[47..59] Purification) (CC:[60..63] and) (NNS:[64..74] properties)) (PP (IN:[75..77] of) (NP (NP (NP (NN:[78..88] cytochrome) (NN:[89..94] P-450)) (VP (ADVP (RB:[95..104] generally)) (VBG:[105..111] acting) (PP-MNR (IN:[112..114] as) (NP (NP (DT:[115..116] a) (NN:[117..125] catalyst)) (PP (IN:[127..129] on) (NP (NN:[130..144] benzo-LSB-a-RSB-pyrene) (NN:[145..158] hydroxylation))))))) (PP (IN:[159..163] from) (NP (NP (NN:[164..169] liver) (NNS:[170..180] microsomes)) (PP (IN:[181..183] of) (NP (JJ:[184..193] untreated) (NNS:[194..198] rats))))))) (.:[198..199] .))) ;section 2 Span:203..231 ;Ohgiya N, Yokota H, Yuasa A. (SEC (FRAG (NNP:[203..209] Ohgiya) (NNP:[210..211] N) (,:[211..212] ,) (NNP:[213..219] Yokota) (NNP:[220..222] H,) (NNP:[223..228] Yuasa) (NNP:[229..230] A) (.:[230..231] .))) ;section 3 Span:235..341 ;Department of Veterinary Biochemistry, School of Veterinary Medicine, Rakuno ;Gakuen University, Hokkaido. (SEC (FRAG (NNP:[235..245] Department) (IN:[246..248] of) (NNP:[249..259] Veterinary) (NNP:[260..272] Biochemistry) (,:[272..273] ,) (NNP:[274..280] School) (IN:[281..283] of) (NNP:[284..294] Veterinary) (NNP:[295..303] Medicine) (,:[303..304] ,) (NNP:[305..311] Rakuno) (NNP:[313..319] Gakuen) (NNP:[320..330] University) (,:[330..331] ,) (NNP:[332..340] Hokkaido) (.:[340..341] .))) ;sentence 4 Span:345..524 ;A form of cytochrome P-450 generally catalyzing benzo[a]pyrene (B[a]P) ;hydroxylation was purified from liver microsomes of untreated rats on the ;basis of the catalytic activity. ;[355..371]:cyp450:"cytochrome P-450" ;[393..407]:substance:"benzo[a]pyrene" ;[409..414]:substance:"B[a]P" (SENT (S (NP-SBJ-1 (NP (DT:[345..346] A) (NN:[347..351] form)) (PP (IN:[352..354] of) (NP (NP (NN:[355..365] cytochrome) (NN:[366..371] P-450)) (VP (ADVP (RB:[372..381] generally)) (VBG:[382..392] catalyzing) (NP (NML (NML (NN:[393..407] benzo-LSB-a-RSB-pyrene)) (NML (-LRB-:[408..409] -LRB-) (NN:[409..414] B-LSB-a-RSB-P) (-RRB-:[414..415] -RRB-))) (NN:[417..430] hydroxylation)))))) (VP (VBD:[431..434] was) (VP (VBN:[435..443] purified) (NP-1 (-NONE-:[443..443] *)) (PP (IN:[444..448] from) (NP (NP (NN:[449..454] liver) (NNS:[455..465] microsomes)) (PP (IN:[466..468] of) (NP (JJ:[469..478] untreated) (NNS:[479..483] rats))))) (PP (IN:[484..486] on) (NP (NP (DT:[487..490] the) (NN:[491..496] basis)) (PP (IN:[498..500] of) (NP (DT:[501..504] the) (JJ:[505..514] catalytic) (NN:[515..523] activity))))))) (.:[523..524] .))) ;sentence 5 Span:525..705 ;The purification procedures consisted of cholate solubilization and ;chromatography in 3 steps, on DEAE-Toyopearl (at room temperature), ;hydroxylapatite, and CM-Toyopearl columns. ;[566..573]:substance:"cholate" ;[624..638]:substance:"DEAE-Toyopearl" ;[663..678]:substance:"hydroxylapatite" ;[684..696]:substance:"CM-Toyopearl" (SENT (S (NP-SBJ (DT:[525..528] The) (NN:[529..541] purification) (NNS:[542..552] procedures)) (VP (VBD:[553..562] consisted) (PP-CLR (IN:[563..565] of) (NP (NP (NP (NN:[566..573] cholate) (NN:[575..589] solubilization)) (CC:[590..593] and) (NP (NP (NN:[594..608] chromatography)) (PP (IN:[609..611] in) (NP (CD:[612..613] 3) (NNS:[614..619] steps))))) (,:[619..620] ,) (PP (IN:[621..623] on) (NP (NP (NN:[624..638] DEAE-Toyopearl) (PRN (-LRB-:[639..640] -LRB-) (PP (IN:[640..642] at) (NP (NN:[643..647] room) (NN:[649..660] temperature))) (-RRB-:[660..661] -RRB-)) (NML-1 (-NONE-:[661..661] *P*))) (,:[661..662] ,) (NP (NN:[663..678] hydroxylapatite) (NML-1 (-NONE-:[678..678] *P*))) (,:[678..679] ,) (CC:[680..683] and) (NP (NN:[684..696] CM-Toyopearl) (NML-1 (NNS:[697..704] columns)))))))) (.:[704..705] .))) ;sentence 6 Span:706..877 ;Cytochrome P-450 purified in this way (named P-450/B[a]P) was homogeneous on ;SDS-polyacrylamide gel electrophoresis, and the molecular weight was ;estimated to be 51,000. ;[706..722]:cyp450:"Cytochrome P-450" ;[752..757]:cyp450:"P-450" ;[758..763]:substance:"B[a]P" ;[870..876]:quantitative-value:"51,000" (SENT (S (S (NP-SBJ (NP (NN:[706..716] Cytochrome) (NN:[717..722] P-450)) (VP (VBN:[724..732] purified) (NP (-NONE-:[732..732] *)) (PP (IN:[733..735] in) (NP (DT:[736..740] this) (NN:[741..744] way)))) (PRN (-LRB-:[745..746] -LRB-) (VP (VBN:[746..751] named) (NP (NN:[752..757] P-450) (SYM:[757..758] /) (NN:[758..763] B-LSB-a-RSB-P))) (-RRB-:[763..764] -RRB-))) (VP (VBD:[765..768] was) (ADJP-PRD (JJ:[769..780] homogeneous)) (PP-LOC (IN:[781..783] on) (NP (NML (NN:[784..802] SDS-polyacrylamide) (NN:[804..807] gel)) (NN:[808..823] electrophoresis))))) (,:[823..824] ,) (CC:[825..828] and) (S (NP-SBJ-1 (DT:[829..832] the) (JJ:[833..842] molecular) (NN:[843..849] weight)) (VP (VBD:[850..853] was) (VP (VBN:[854..863] estimated) (S (NP-SBJ-1 (-NONE-:[863..863] *)) (VP (TO:[864..866] to) (VP (VB:[867..869] be) (NP-PRD (CD:[870..876] 51,000)))))))) (.:[876..877] .))) ;sentence 7 Span:878..1087 ;The absorption spectra of the oxidized form of P-450/B[a]P showed a Soret ;peak at 417 nm, characteristic of low-spin hemoprotein, and the Soret peak ;of the reduced cytochrome P-450-CO complex was at 451 nm. ;[926..931]:cyp450:"P-450" ;[932..937]:substance:"B[a]P" ;[962..965]:quantitative-value:"417" ;[966..968]:quantitative-units:"nm" ;[997..1008]:substance:"hemoprotein" ;[1045..1072]:substance:"cytochrome P-450-CO complex" ;[1080..1083]:quantitative-value:"451" ;[1084..1086]:quantitative-units:"nm" (SENT (S (S (NP-SBJ (NP (DT:[878..881] The) (NN:[883..893] absorption) (NNS:[894..901] spectra)) (PP (IN:[902..904] of) (NP (NP (DT:[905..908] the) (VBN:[909..917] oxidized) (NN:[918..922] form)) (PP (IN:[923..925] of) (NP (NN:[926..931] P-450) (SYM:[931..932] /) (NN:[932..937] B-LSB-a-RSB-P)))))) (VP (VBD:[938..944] showed) (NP (NP (DT:[945..946] a) (NNP:[947..952] Soret) (NN:[953..957] peak)) (PP (IN:[958..960] at) (NP (CD:[962..965] 417) (NN:[966..968] nm)))) (,:[968..969] ,) (S-ADV (NP-SBJ (-NONE-:[969..969] *)) (ADJP-PRD (JJ:[970..984] characteristic) (PP (IN:[985..987] of) (NP (NML (JJ:[988..991] low) (HYPH:[991..992] -) (NN:[992..996] spin)) (NN:[997..1008] hemoprotein))))))) (,:[1008..1009] ,) (CC:[1010..1013] and) (S (NP-SBJ (NP (DT:[1014..1017] the) (NNP:[1018..1023] Soret) (NN:[1024..1028] peak)) (PP (IN:[1029..1031] of) (NP (DT:[1032..1035] the) (VBN:[1037..1044] reduced) (NML (NML (NN:[1045..1055] cytochrome) (NN:[1056..1061] P-450)) (HYPH:[1061..1062] -) (NN:[1062..1064] CO)) (NN:[1065..1072] complex)))) (VP (VBD:[1073..1076] was) (PP-LOC-PRD (IN:[1077..1079] at) (NP (CD:[1080..1083] 451) (NN:[1084..1086] nm))))) (.:[1086..1087] .))) ;sentence 8 Span:1088..1363 ;Immunochemical analysis of P-450/B[a]P indicated that P-450/B[a]P is ;immunologically distinct from P-450b (a major phenobarbital-inducible form ;of P-450) and P-450c (a major 3-methylcholanthrene-inducible form of P-450, ;which highly catalyzes the hydroxylation of B[a]P). ;[1116..1121]:cyp450:"P-450" ;[1122..1127]:substance:"B[a]P" ;[1143..1148]:cyp450:"P-450" ;[1149..1154]:substance:"B[a]P" ;[1188..1194]:cyp450:"P-450b" ;[1205..1218]:substance:"phenobarbital" ;[1237..1242]:cyp450:"P-450" ;[1248..1254]:cyp450:"P-450c" ;[1265..1285]:substance:"3-methylcholanthrene" ;[1304..1309]:cyp450:"P-450" ;[1356..1361]:substance:"B[a]P" (SENT (S (NP-SBJ (NP (JJ:[1088..1102] Immunochemical) (NN:[1103..1111] analysis)) (PP (IN:[1112..1114] of) (NP (NN:[1116..1121] P-450) (SYM:[1121..1122] /) (NN:[1122..1127] B-LSB-a-RSB-P)))) (VP (VBD:[1128..1137] indicated) (SBAR (IN:[1138..1142] that) (S (NP-SBJ (NN:[1143..1148] P-450) (SYM:[1148..1149] /) (NN:[1149..1154] B-LSB-a-RSB-P)) (VP (VBZ:[1155..1157] is) (ADJP-PRD (RB:[1158..1173] immunologically) (JJ:[1174..1182] distinct) (PP (IN:[1183..1187] from) (NP (NP (NN:[1188..1194] P-450b) (PRN (-LRB-:[1196..1197] -LRB-) (NP (NP (DT:[1197..1198] a) (JJ:[1199..1204] major) (ADJP (NN:[1205..1218] phenobarbital) (HYPH:[1218..1219] -) (JJ:[1219..1228] inducible)) (NN:[1229..1233] form)) (PP (IN:[1234..1236] of) (NP (NN:[1237..1242] P-450)))) (-RRB-:[1242..1243] -RRB-))) (CC:[1244..1247] and) (NP (NN:[1248..1254] P-450c) (PRN (-LRB-:[1255..1256] -LRB-) (NP (NP (NP (DT:[1256..1257] a) (JJ:[1258..1263] major) (ADJP (NN:[1265..1285] 3-methylcholanthrene) (HYPH:[1285..1286] -) (JJ:[1286..1295] inducible)) (NN:[1296..1300] form)) (PP (IN:[1301..1303] of) (NP (NN:[1304..1309] P-450)))) (,:[1309..1310] ,) (SBAR (WHNP-1 (WDT:[1311..1316] which)) (S (NP-SBJ-1 (-NONE-:[1316..1316] *T*)) (ADVP (RB:[1317..1323] highly)) (VP (VBZ:[1324..1333] catalyzes) (NP (NP (DT:[1334..1337] the) (NN:[1339..1352] hydroxylation)) (PP (IN:[1353..1355] of) (NP (NN:[1356..1361] B-LSB-a-RSB-P)))))))) (-RRB-:[1361..1362] -RRB-)))))))))) (.:[1362..1363] .))) ;sentence 9 Span:1364..1485 ;B[a]P hydroxylase activity in liver microsomes of untreated rats was ;inhibited to about 20% by the P-450/B[a]P antibody. ;[1364..1381]:substance:"B[a]P hydroxylase" ;[1453..1456]:quantitative-value:"20%" ;[1464..1484]:substance:"P-450/B[a]P antibody" (SENT (S (NP-SBJ-1 (NP (NN:[1364..1369] B-LSB-a-RSB-P) (NN:[1370..1381] hydroxylase) (NN:[1382..1390] activity)) (PP-LOC (IN:[1391..1393] in) (NP (NP (NN:[1394..1399] liver) (NNS:[1400..1410] microsomes)) (PP (IN:[1411..1413] of) (NP (JJ:[1415..1424] untreated) (NNS:[1425..1429] rats)))))) (VP (VBD:[1430..1433] was) (VP (VBN:[1434..1443] inhibited) (NP-1 (-NONE-:[1443..1443] *)) (PP (TO:[1444..1446] to) (NP-EXT (QP (RB:[1447..1452] about) (CD:[1453..1455] 20)) (NN:[1455..1456] %))) (PP (IN:[1457..1459] by) (NP-LGS (DT:[1460..1463] the) (NML (NN:[1464..1469] P-450) (SYM:[1469..1470] /) (NN:[1470..1475] B-LSB-a-RSB-P)) (NN:[1476..1484] antibody))))) (.:[1484..1485] .))) ;sentence 10 Span:1486..1667 ;These results demonstrate that P-450/B[a]P is a different form of P-450 from ;P-450b and P-450c, and generally catalyzes B[a]P hydroxylation in liver ;microsomes of untreated rats. ;[1518..1523]:cyp450:"P-450" ;[1524..1529]:substance:"B[a]P" ;[1553..1558]:cyp450:"P-450" ;[1564..1570]:cyp450:"P-450b" ;[1576..1582]:cyp450:"P-450c" ;[1608..1613]:substance:"B[a]P" (SENT (S (NP-SBJ (DT:[1486..1491] These) (NNS:[1493..1500] results)) (VP (VBP:[1501..1512] demonstrate) (SBAR (IN:[1513..1517] that) (S (NP-SBJ (NN:[1518..1523] P-450) (SYM:[1523..1524] /) (NN:[1524..1529] B-LSB-a-RSB-P)) (VP (VP (VBZ:[1530..1532] is) (NP-PRD (NP (DT:[1533..1534] a) (JJ:[1535..1544] different) (NN:[1545..1549] form)) (PP (IN:[1550..1552] of) (NP (NP (NN:[1553..1558] P-450)) (PP (IN:[1559..1563] from) (NP (NN:[1564..1570] P-450b) (CC:[1572..1575] and) (NN:[1576..1582] P-450c))))))) (,:[1582..1583] ,) (CC:[1584..1587] and) (VP (ADVP (RB:[1588..1597] generally)) (VBZ:[1598..1607] catalyzes) (NP (NN:[1608..1613] B-LSB-a-RSB-P) (NN:[1614..1627] hydroxylation)) (PP-LOC (IN:[1628..1630] in) (NP (NP (NN:[1631..1636] liver) (NNS:[1637..1647] microsomes)) (PP (IN:[1648..1650] of) (NP (JJ:[1652..1661] untreated) (NNS:[1662..1666] rats)))))))))) (.:[1666..1667] .))) ;section 11 Span:1671..1715 ;PMID: 2498299 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1671..1675] PMID) (::[1675..1676] :) (CD:[1677..1684] 2498299) (NN:[1685..1686] -LSB-) (NNP:[1686..1692] PubMed) (::[1693..1694] -) (NN:[1695..1702] indexed) (IN:[1703..1706] for) (NNP:[1707..1715] MEDLINE-RSB-)))